Our Approach to Hypertrophic & Infiltrative Cardiomyopathy
Montefiore Einstein Hypertrophic and Infiltrative Cardiomyopathy (HCM) Programs are leaders in the field with decades of experience treating individuals and families with these genetic conditions. Our highly specialized HCM team brings together clinical examinations, state-of-the-art laboratories, the latest genetic testing and the most advanced cardiac imaging to diagnose and determine the best treatment options for your HCM. We’re ranked in the top 1% of all hospitals in the nation for Cardiology, Heart & Vascular Surgery according to U.S. News & World Report.
Understanding HCM
HCM affects one out of every 500 people and causes the heart muscle to become abnormally thick, making it harder to pump blood.
State-of-the-Art Cardiomyopathy Services
Montefiore Einstein’s HCM Program is dedicated to the diagnosis and care of patients and families with or at risk for HCM. At Montefiore Einstein, our multi-disciplinary team uses the latest technology to evaluate, diagnose and treat each individual.
Our world-renowned heart specialists will perform a series of assessments which may include a cardiac MRI, stress testing and genetic counseling. You will also be evaluated for HCM-associated conditions including atrial fibrillation and microvascular dysfunction.
Montefiore Einstein’s HCM team works closely with our Center for CardioGenetics to provide families affected by this disease with an interdisciplinary approach for genetic screening, DNA analysis, and counseling.
Our cardiologists and cardiothoracic surgeons are highly experienced in the latest treatment options, including hypertrophy correction, catheter-based heart rhythm therapies, surgical septal reduction therapies (one of the few centers worldwide to perform this procedure to relieve obstruction of blood flow), comprehensive surgical septal reduction therapy (which combines septal myomectomy with mitral valve repair and/or papillary muscle reorientation) and device implantation to prevent sudden cardiac death. Our expert teams also use novel therapies such as Mavacamten, a medication used to treat hypertrophic obstructive cardiomyopathy.
Your Heart Team
We’re home to hundreds of heart and vascular experts, many recognized around the world for their contributions to medicine and science—and appreciated deeply by patients and families for the compassionate care they provide.
Mario J. Garcia, MD
Aldo L. Schenone, MD
Yogita M. Rochlani, MD
